| Website | calistogapharma.com |
| Category | BioTech |
| Phone | 206-728-4700 |
| Employees | |
| Description | Cancer & Inflammatory Disease Treatment |
| Series B, 5/09 Alta Partners Frazier Healthcare Ventures Three Arch Partners Amgen Ventures | $30M |
Calistoga Pharmaceuticals is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases. Calistoga Pharmaceuticals has a portfolio of proprietary compounds selectively targeting the isoforms of the PI3 kinase pathway.
